Base de dados : MEDLINE
Pesquisa : C18.452.174 [Categoria DeCS]
Referências encontradas : 1170 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 117 ir para página                         

  1 / 1170 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28336828
[Au] Autor:Michigami T
[Ad] Endereço:Disorders Caused by Mutations in Calcium-Sensing Receptor and Related Diseases.
[Ti] Título:[Disorders Caused by Mutations in Calcium-Sensing Receptor and Related Diseases.]
[So] Source:Clin Calcium;27(4):521-527, 2017.
[Is] ISSN:0917-5857
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Sensing of extracellular calcium(Ca2+)levels involves the Ca-sensing receptor(CaSR), its downstream signaling molecule Gα11, and the adaptor-related protein complex 2(AP2)that plays a role in clathrin-dependent endocytosis of CaSR. Inactivating mutations in CaSR cause familial hypocalciuric hypercalcemia type 1(FHH1)and neonatal severe hyperparathyroidism(NSHPT), while activating mutations lead to autosomal dominant hypocalcemia type 1(ADH1)and Bartter syndrome type â…¤. Recent studies have identified that inactivating mutations in Gα11 and σ-subunit of AP2(AP2σ)also cause FHH, and these conditions have been classified as FHH2 and FHH3, respectively. In addition, it has been revealed that activating mutations in Gα11 are responsible for ADH(ADH2). Calcimimetics and calcilytics may be beneficial in the treatment of these disorders.
[Mh] Termos MeSH primário: Distúrbios do Metabolismo do Cálcio/metabolismo
Mutação
Receptores de Detecção de Cálcio/metabolismo
[Mh] Termos MeSH secundário: Cálcio/metabolismo
Distúrbios do Metabolismo do Cálcio/genética
Sinalização do Cálcio
Seres Humanos
Transporte Proteico
Receptores de Detecção de Cálcio/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, Calcium-Sensing); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE
[do] DOI:CliCa1704521527


  2 / 1170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
[PMID]:27905644
[Au] Autor:Salinas M; López-Garrigós M; Flores E; Uris J; Leiva-Salinas C
[Ti] Título:Requests of laboratory tests for the diagnosis and management of calcium-phosphate disorders in Spain.
[So] Source:Rev Med Chil;144(8):990-997, 2016 Aug.
[Is] ISSN:0717-6163
[Cp] País de publicação:Chile
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Knowledge about the variability in the request of calcium-phosphate metabolism laboratory tests in primary care is important to design strategies to improve health system efficiency. AIM: To compare the inter-practice variability in calcium-phosphate metabolism laboratory tests requested by general practitioners from diverse regions across Spain. MATERIAL AND METHODS: One hundred and forty one clinical laboratories were invited to participate in an observational cross-sectional study. They informed the number of serum calcium, phosphate, parathyroid hormone and 25-hydroxyvitamin D requested by general practitioners. Appropriateness indicators were calculated as number of test requests per 1,000 inhabitants and ratio of related tests requests. The differences according to hospital setting, region and type of management were analyzed. RESULTS: We recruited 76 laboratories (17,679,195 inhabitants). General practitioners requested 3,260,894 calcium-phosphate metabolism tests. The rate of request ranged from 2.97 per 1,000 inhabitants for 25-hydroxyvitamin D to 98.89 per 1,000 inhabitants for calcium. The rates of request for calcium, phosphate, parathyroid hormone in some areas were 30, 100 and 340 times higher than in other areas. Parathyroid hormone and 25-hydroxyvitamin D were highly requested in private management areas. There were also differences in phosphate, parathyroid hormone and 25-hydroxyvitamin D requesting between regions across Spain. CONCLUSIONS: The high variability observed is difficult to explain by differences in patient case mix between regions. Depending on the area, calcium could be under requested to detect primary hyperparathyroidism.
[Mh] Termos MeSH primário: Distúrbios do Metabolismo do Cálcio/diagnóstico
Técnicas de Laboratório Clínico/utilização
Clínicos Gerais
Programas de Rastreamento/métodos
Padrões de Prática Médica
Atenção Primária à Saúde/estatística & dados numéricos
[Mh] Termos MeSH secundário: Fosfatos de Cálcio/sangue
Fosfatos de Cálcio/metabolismo
Estudos Transversais
Feminino
Seres Humanos
Hipercalcemia/diagnóstico
Hiperparatireoidismo/diagnóstico
Masculino
Hormônio Paratireóideo/sangue
Fosfatos/sangue
Espanha
Vitamina D/análogos & derivados
Vitamina D/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Calcium Phosphates); 0 (Parathyroid Hormone); 0 (Phosphates); 1406-16-2 (Vitamin D); 64719-49-9 (25-hydroxyvitamin D); 97Z1WI3NDX (calcium phosphate)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170526
[Lr] Data última revisão:
170526
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161202
[St] Status:MEDLINE


  3 / 1170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27868419
[Au] Autor:DU M; Ma G; Shi Y
[Ad] Endereço:Department of Cardiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
[Ti] Título:[Research progress on pharmacotherapy of calcific aortic valve disease].
[So] Source:Zhejiang Da Xue Xue Bao Yi Xue Ban;45(4):432-438, 2016 May 25.
[Is] ISSN:1008-9292
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:With the population aging and declining incidence of rheumatic heart disease, calcific aortic valve disease (CAVD) has become the most frequent valve disease and the common cause of aortic valve replacement. Patients with CAVD need to cope with a deteriorating quality of life and valve replacement is the only effective clinical option for the patients. Therefore, early pharmacotherapy is of great significance in prevention or slow-down of the progression of CAVD. For years CAVD was considered to be a passive wear and tear process of valves, but now it is recognized as an active and multi-factorial process. Histopathologic studies have revealed that inflammation, disorder of calcium and phosphorus metabolism and dyslipidemia are involved in the process of CAVD. Clinical trials of CAVD pharmacotherapy have been carried out based on those histopathologic studies. Statin, renin-angiotensin inhibitors and anti-osteoporosis drug are well studied in recent years. This article reviews the recent research progress of the pharmacotherapy for CAVD.
[Mh] Termos MeSH primário: Estenose da Valva Aórtica/tratamento farmacológico
Valva Aórtica/patologia
Calcinose/tratamento farmacológico
[Mh] Termos MeSH secundário: Antagonistas de Receptores de Angiotensina/uso terapêutico
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Estenose da Valva Aórtica/complicações
Estenose da Valva Aórtica/etiologia
Calcinose/complicações
Calcinose/etiologia
Distúrbios do Metabolismo do Cálcio/complicações
Progressão da Doença
Dislipidemias/complicações
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Inflamação/complicações
Distúrbios do Metabolismo do Fósforo/complicações
Qualidade de Vida
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Angiotensin Receptor Antagonists); 0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161122
[St] Status:MEDLINE


  4 / 1170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27643936
[Au] Autor:Tribulova N; Knezl V; Szeiffova Bacova B; Egan Benova T; Viczenczova C; Gonçalvesova E; Slezak J
[Ad] Endereço:Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic. narcisa.tribulova@savba.sk.
[Ti] Título:Disordered myocardial Ca(2+) homeostasis results in substructural alterations that may promote occurrence of malignant arrhythmias.
[So] Source:Physiol Res;65 Suppl 1:S139-48, 2016 Sep 19.
[Is] ISSN:1802-9973
[Cp] País de publicação:Czech Republic
[La] Idioma:eng
[Ab] Resumo:We aimed to determine the impact of Ca(2+)-related disorders induced in intact animal hearts on ultrastructure of the cardiomyocytes prior to occurrence of severe arrhythmias. Three types of acute experiments were performed that are known to be accompanied by disturbances in Ca(2+) handling. Langedorff-perfused rat or guinea pig hearts subjected to K(+)-deficient perfusion to induce ventricular fibrillation (VF), burst atrial pacing to induce atrial fibrillation (AF) and open chest pig heart exposed to intramyocardial noradrenaline infusion to induce ventricular tachycardia (VT). Tissue samples for electron microscopic examination were taken during basal condition, prior and during occurrence of malignant arrhythmias. Cardiomyocyte alterations preceding occurrence of arrhythmias consisted of non-uniform sarcomere shortening, disruption of myofilaments and injury of mitochondria that most likely reflected cytosolic Ca(2+) disturbances and Ca(2+) overload. These disorders were linked with non-uniform pattern of neighboring cardiomyocytes and dissociation of adhesive junctions suggesting defects in cardiac cell-to-cell coupling. Our findings identified heterogeneously distributed high [Ca(2+)](i)-induced subcellular injury of the cardiomyocytes and their junctions as a common feature prior occurrence of VT, VF or AF. In conclusion, there is a link between Ca(2+)-related disorders in contractility and coupling of the cardiomyocytes pointing out a novel paradigm implicated in development of severe arrhythmias.
[Mh] Termos MeSH primário: Arritmias Cardíacas/etiologia
Distúrbios do Metabolismo do Cálcio/complicações
Miócitos Cardíacos/ultraestrutura
[Mh] Termos MeSH secundário: Animais
Arritmias Cardíacas/metabolismo
Distúrbios do Metabolismo do Cálcio/patologia
Cobaias
Homeostase
Miócitos Cardíacos/metabolismo
Norepinefrina
Potássio
Ratos
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
RWP5GA015D (Potassium); X4W3ENH1CV (Norepinephrine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170407
[Lr] Data última revisão:
170407
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160920
[St] Status:MEDLINE


  5 / 1170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27487342
[Au] Autor:Forssmann WG; Tillmann HC; Hock D; Forssmann K; Bernasconi C; Forssmann U; Richter R; Hocher B; Pfützner A
[Ad] Endereço:IPF PharmaCeuticals GmbH, Hannover, Germany.
[Ti] Título:Pharmacokinetic and Pharmacodynamic Characteristics of Subcutaneously Applied PTH-1-37.
[So] Source:Kidney Blood Press Res;41(5):507-518, 2016.
[Is] ISSN:1423-0143
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: Parathyroid hormone (PTH) derivatives exert pronounced renal and osteoanabolic properties when given intermittently. The current study was performed to assess the pharmacokinetic and pharmacodynamic properties as well as safety of subcutaneously applied PTH-1-37 after repeated dosing in healthy subjects. METHODS: This randomized, double-blind, dose-escalating, placebo and active comparator controlled study was conducted in 33 healthy postmenopausal women. Subjects were allocated to one of five treatment options: 10, 20, or 40 µg PTH-1-37, 20 µg PTH-1-34 or placebo, administered as once daily subcutaneous doses for three days. Plasma drug concentrations and serum levels of endogenous PTH-1-84, and calcium as markers of biological activity were monitored during the treatment. RESULTS: PTH was absorbed rapidly from the subcutaneous tissue with a median tmax of 30 minutes for 20 and 40 µg of PTH-1-37. tmax was 45 minutes for 20 µg PTH-1-34. Elimination half-lives were estimated as 76 ± 34 min and 70 ± 13 min for 20 µg and 40 µg PTH-1-37 (mean ± SD), and 78 ± 34 for 20 µg PTH-1-34. Both PTH fragments (PTH-1-37 and PTH-1-34) increased serum calcium. For PTH-1-37 the effect on serum calcium was dose-dependent. Suppression of endogenous PTH-1-84 was seen after the application of both PTH-1-37 and PTH-1-34. During the study period, the subjects experienced no unexpected or serious adverse events. CONCLUSIONS: PTH-1-37 is rapidly absorbed after s.c. injection, has a short plasma elimination half-life, and does not accumulate during multiple dosing. Biological activity was demonstrated by rising serum calcium and decreasing endogenous PTH-1-84 in blood plasma. The study drugs were well tolerated and safe. Our investigation presents data that PTH-1-37 is an excellent drug candidate for intervening with syndromes of dysregulation of calcium metabolism.
[Mh] Termos MeSH primário: Hormônio Paratireóideo/farmacocinética
Fragmentos de Peptídeos/farmacocinética
[Mh] Termos MeSH secundário: Cálcio/sangue
Cálcio/metabolismo
Distúrbios do Metabolismo do Cálcio/tratamento farmacológico
Relação Dose-Resposta a Droga
Método Duplo-Cego
Feminino
Meia-Vida
Voluntários Saudáveis
Seres Humanos
Injeções Subcutâneas
Meia-Idade
Hormônio Paratireóideo/administração & dosagem
Hormônio Paratireóideo/sangue
Fragmentos de Peptídeos/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Parathyroid Hormone); 0 (Peptide Fragments); 0 (parathyroid hormone (1-37)); 0 (parathyroid hormone (1-38)); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170407
[Lr] Data última revisão:
170407
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160804
[St] Status:MEDLINE


  6 / 1170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26945509
[Au] Autor:Haffner-Luntzer M; Heilmann A; Heidler V; Liedert A; Schinke T; Amling M; Yorgan TA; Vom Scheidt A; Ignatius A
[Ad] Endereço:Institute of Orthopedic Research and Biomechanics, University Medical Center Ulm, Helmholtzstraße 14, Ulm, 89081, Germany.
[Ti] Título:Hypochlorhydria-induced calcium malabsorption does not affect fracture healing but increases post-traumatic bone loss in the intact skeleton.
[So] Source:J Orthop Res;34(11):1914-1921, 2016 Nov.
[Is] ISSN:1554-527X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Efficient calcium absorption is essential for skeletal health. Patients with impaired gastric acidification display low bone mass and increased fracture risk because calcium absorption is dependent on gastric pH. We investigated fracture healing and post-traumatic bone turnover in mice deficient in Cckbr, encoding a gastrin receptor that affects acid secretion by parietal cells. Cckbr-/- mice display hypochlorhydria, calcium malabsorption, and osteopenia. Cckbr-/- and wildtype (WT) mice received a femur osteotomy and were fed either a standard or calcium-enriched diet. Healed and intact bones were assessed by biomechanical testing, histomorphometry, micro-computed tomography, and quantitative backscattering. Parathyroid hormone (PTH) serum levels were determined by enzyme-linked immunosorbent assay. Fracture healing was unaffected in Cckbr-/- mice. However, Cckbr-/- mice displayed increased calcium mobilization from the intact skeleton during bone healing, confirmed by significantly elevated PTH levels and osteoclast numbers compared to WT mice. Calcium supplementation significantly reduced secondary hyperparathyroidism and bone resorption in the intact skeleton in both genotypes, but more efficiently in WT mice. Furthermore, calcium administration improved bone healing in WT mice, indicated by significantly increased mechanical properties and bone mineral density of the fracture callus, whereas it had no significant effect in Cckbr-/- mice. Therefore, under conditions of hypochlorhydria-induced calcium malabsorption, calcium, which is essential for callus mineralization, appears to be increasingly mobilized from the intact skeleton in favor of fracture healing. Calcium supplementation during fracture healing prevented systemic calcium mobilization, thereby maintaining bone mass and improving fracture healing in healthy individuals whereas the effect was limited by gastric hypochlorhydria. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:1914-1921, 2016.
[Mh] Termos MeSH primário: Acloridria/complicações
Reabsorção Óssea/etiologia
Distúrbios do Metabolismo do Cálcio/fisiopatologia
Fraturas do Fêmur/complicações
Consolidação da Fratura
[Mh] Termos MeSH secundário: Animais
Cálcio/metabolismo
Cálcio/uso terapêutico
Distúrbios do Metabolismo do Cálcio/complicações
Suplementos Nutricionais
Feminino
Fraturas do Fêmur/metabolismo
Camundongos
Distribuição Aleatória
Receptor de Colecistocinina B/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptor, Cholecystokinin B); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160307
[St] Status:MEDLINE
[do] DOI:10.1002/jor.23221


  7 / 1170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26119316
[Au] Autor:Endo I
[Ad] Endereço:Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan.
[Ti] Título:[Bone and Nutrition. A prospect of calcium sensing receptor].
[So] Source:Clin Calcium;25(7):1029-36, 2015 Jul.
[Is] ISSN:0917-5857
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Following the discovery of the calcium-sensing receptor (CaSR) in 1993, its pivotal role in disorders of calcium homeostasis was demonstrated. Compelling evidence suggests that the CaSR plays multiple roles extending well beyond not only regulating the level of extracellular Ca(2+), but also controlling diverse and crucial roles in human physiology and pathophysiology. This review covers current knowledge of the role of the CaSR in disorders of calcium homeostasis (familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, autosomal dominant hypocalcemia, primary and secondary hyperparathyroidism, hypercalcemia of malignancy) as well as unrelated diseases such as breast and colorectal cancer, Alzheimer's disease and pancreatitis. In addition, it examines the use or potential use of CaSR agonists or antagonists in the management of disorders as diverse as hyperparathyroidism and Alzheimer's disease.
[Mh] Termos MeSH primário: Distúrbios do Metabolismo do Cálcio/etiologia
Cálcio/metabolismo
Receptores de Detecção de Cálcio/fisiologia
[Mh] Termos MeSH secundário: Doença de Alzheimer/etiologia
Animais
Neoplasias da Mama/etiologia
Neoplasias Colorretais/etiologia
Feminino
Homeostase
Seres Humanos
Masculino
Camundongos
Terapia de Alvo Molecular
Mutação
Pancreatite
Receptores de Detecção de Cálcio/agonistas
Receptores de Detecção de Cálcio/antagonistas & inibidores
Receptores de Detecção de Cálcio/genética
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Receptors, Calcium-Sensing); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:150629
[Lr] Data última revisão:
150629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150630
[St] Status:MEDLINE
[do] DOI:CliCa150710291036


  8 / 1170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25634043
[Au] Autor:Yamaguchi K
[Ad] Endereço:Fukuro Clinic Todoroki, Sofukukai Medical Corporation, Japan.
[Ti] Título:[Cognitive Function and Calcium. The link between dementia and bone and calcium metabolism disorders].
[So] Source:Clin Calcium;25(2):189-94, 2015 Feb.
[Is] ISSN:0917-5857
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Bone and calcium metabolism disorders are closely linked with dementia. Screening for dementia is important since chronic hypercalcemia and hypocalcemia resulting from parathyroid function abnormalities can become a cause of dementia onset. In recent years, it has become clear that vitamin D deficiencies inducing cardiovascular disease and other factors are involved in the pathogenesis of various diseases that in turn become risk factors in dementia, especially Alzheimer's disease. Moreover, osteoporosis and dementia both commonly occur among the elderly. Treating dementia patients for osteoporosis is important since fragility fractures, especially femoral neck fractures, resulting from osteoporosis greatly affect the prognosis of patients with dementia.
[Mh] Termos MeSH primário: Osso e Ossos/metabolismo
Distúrbios do Metabolismo do Cálcio/metabolismo
Cálcio/metabolismo
Demência/metabolismo
Osteoporose/metabolismo
[Mh] Termos MeSH secundário: Animais
Distúrbios do Metabolismo do Cálcio/complicações
Distúrbios do Metabolismo do Cálcio/terapia
Cognição/fisiologia
Demência/complicações
Demência/terapia
Seres Humanos
Osteoporose/complicações
Osteoporose/terapia
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
SY7Q814VUP (Calcium)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:150130
[Lr] Data última revisão:
150130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150131
[St] Status:MEDLINE
[do] DOI:CliCa1502189194


  9 / 1170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27522799
[Au] Autor:Takeuchi Y
[Ti] Título:[111th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: 17. Emerging clinical questions of calcium metabolism disorders and promising therapeutic approaches to them].
[So] Source:Nihon Naika Gakkai Zasshi;103(9):2342-7, 2014 Sep 10.
[Is] ISSN:0021-5384
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Mh] Termos MeSH primário: Distúrbios do Metabolismo do Cálcio/metabolismo
[Mh] Termos MeSH secundário: Doenças Ósseas/tratamento farmacológico
Doenças Ósseas/etiologia
Distúrbios do Metabolismo do Cálcio/tratamento farmacológico
Distúrbios do Metabolismo do Cálcio/etiologia
Fatores de Crescimento de Fibroblastos/metabolismo
Seres Humanos
Neoplasias da Glândula Tireoide/complicações
Neoplasias da Glândula Tireoide/fisiopatologia
Vitamina D/química
Vitamina D/metabolismo
Deficiência de Vitamina D/complicações
Deficiência de Vitamina D/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (fibroblast growth factor 23); 1406-16-2 (Vitamin D); 62031-54-3 (Fibroblast Growth Factors)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160816
[St] Status:MEDLINE


  10 / 1170 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25326053
[Au] Autor:Kasperk C; Bartl H
[Ad] Endereço:Klinik für Endokrinologie, Stoffwechsel und Klinische Chemie, Medizinische Universitätsklinik Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland, christian.kasperk@med.uni-heidelberg.de.
[Ti] Título:[Disorders of calcium metabolism].
[Ti] Título:Störungen des Kalziumstoffwechsels..
[So] Source:Internist (Berl);55(11):1313-26, 2014 Nov.
[Is] ISSN:1432-1289
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:The majority of clinical complaints derive from disorders of calcium metabolism and are associated with a wide variety of clinical symptoms caused by numerous diseases with entirely different types of pathophysiology. The prognosis varies from favorable to fatal depending on the pathophysiology of the underlying disorder of calcium metabolism; therefore, the diagnostic work-up aims to quickly identify the underlying disease causing the disturbance in calcium homeostasis. Every clinical situation with a diminished state of calcium absorption is treated with calcium and vitamin D in varying doses whereas every disorder with an increased calcium absorptive or resorptive state is treated with improved diuresis in addition to antiresorptive drugs, such as bisphosphonates. In many situations the management of a disturbed calcium balance requires an interdisciplinary approach in order to treat the underlying disease in parallel with correction of the calcium homeostasis.
[Mh] Termos MeSH primário: Conservadores da Densidade Óssea/administração & dosagem
Doenças Ósseas/prevenção & controle
Distúrbios do Metabolismo do Cálcio/diagnóstico
Distúrbios do Metabolismo do Cálcio/tratamento farmacológico
Cálcio/administração & dosagem
Difosfonatos/administração & dosagem
Vitamina D/administração & dosagem
[Mh] Termos MeSH secundário: Doenças Ósseas/diagnóstico
Doenças Ósseas/etiologia
Distúrbios do Metabolismo do Cálcio/complicações
Diagnóstico Diferencial
Seres Humanos
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Diphosphonates); 1406-16-2 (Vitamin D); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:170916
[Lr] Data última revisão:
170916
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141019
[St] Status:MEDLINE
[do] DOI:10.1007/s00108-014-3610-y



página 1 de 117 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde